Retatrutide
Also known as: Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Pricing for Retatrutide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$7.19/mg
range $1.00–$33.68/mg
Sellers
80
from $0.00
45-day trend
-5.2%
vs 45-day avg $/mg
72 of 80 sellers have a current price· 49 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Peptide Partners99via Disclosed Labs · just now
$3.15/mg -56.2% vs avg$1512
480mg
- 🇺🇸 Reta One Labs95
via Disclosed Labs · just now
$3.98/mg -44.6% vs avg$239
60mg
99.8% purity 58 COAs - 🇺🇸 Profound Aminos95
via Disclosed Labs · just now
$4.93/mg -31.4% vs avg$296
60mg
- 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$5.56/mg -22.8% vs avg$200
36mg
99.8% purity 20 COAs - 🇺🇸 Prime Peptides95
via Disclosed Labs · just now
$7.50/mg +4.3% vs avg$450
60mg
- 🇺🇸 Licensed Peptides95
✓ verified at source · 1d ago
$33.68/mg +368.2% vs avg$2021
60mg
- 🇺🇸 Forge Performance Co.94
via Disclosed Labs · just now
$6.00/mg -16.6% vs avg$180
30mg
- 🇺🇸 Riptide Wellness92
via Disclosed Labs · just now
$5.80/mg -19.4% vs avg$290
50mg
no purity - 🇺🇸 Sunrise Bioresearch88
via Disclosed Labs · just now
$3.44/mg -52.2% vs avg$68.81
20mg
100.0% purity 7 COAs - 🇺🇸 Simple Peptide85
via Disclosed Labs · just now
$7.48/mg +4% vs avg$359
48mg
- Peptide Supply Co.83
via Disclosed Labs · just now
$1.33/mg -81.5% vs avg$800
600mg
99.6% purity 4 COAs - 🇨🇳 Reta Peptide83
✓ verified at source · just now
$13.50/mg +87.7% vs avg$135
10mg
99.5% purity 14 COAs - 🇺🇸 Blank Peptides81
✓ verified at source · just now
$4.33/mg -39.7% vs avg$130
30mg
99.5% purity 4 COAs - 🇺🇸 OROS Research79
via Disclosed Labs · just now
$11.50/mg +59.9% vs avg$230
20mg
99.0% purity 1 COA - 🇺🇸 Texpeptide65
✓ verified at source · 1d ago
$10.00/mg +39% vs avg$100
10mg
- 🇭🇰 Hkuppeptide50
✓ verified at source · just now
$1.00/mg -86.1% vs avg$10.00
10mg
99.8% purity 1 COA - 🇭🇰 zztai Peptide Ltd43
✓ verified at source · just now
$9.33/mg +29.8% vs avg$280
30mg
99.9% purity 1 COA - 🇺🇸 Alpha PeptidesUnscored
via Disclosed Labs · just now
$3.30/mg -54.1% vs avg$165
50mg
no purity - 🇺🇸 NG PeptideUnscored
via Disclosed Labs · just now
$3.30/mg -54.1% vs avg$165
50mg
no purity - volterasciences.comUnscored
via Disclosed Labs · just now
$3.33/mg -53.7% vs avg$200
60mg
no purity - peptidetech.isUnscored
via Disclosed Labs · just now
$4.67/mg -35.1% vs avg$280
60mg
no purity - optimasupply.isUnscored
via Disclosed Labs · just now
$8.83/mg +22.8% vs avg$530
60mg
no purity - realpeptides.coUnscored
via Disclosed Labs · just now
$12.50/mg +73.8% vs avg$300
24mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Retatrutide
429 third-party tests across 43 vendors. Each card links to the full report.
For
Retatrutide
by NG Peptide· batch RT20-09
For
Retatrutide
by Aspire Peptides· batch RT20-032026-1
For
Retatrutide
by Aspire Peptides· batch RT15-032026-1
For
Retatrutide
by Aspire Peptides· batch GLP-3R
For
Retatrutide
by EZ Peptides· batch EZP-3P1206222026-03
For
Retatrutide
by Peptide Partners· batch RTT2613
For
Retatrutide
by EZ Peptides· batch EZP-3P1206222026-03
For
Retatrutide
by Virtus Peptides· batch RT30-655
For
Retatrutide
by Virtus Peptides· batch RT10-655
For
Retatrutide
by Optima Supply· batch OS-2026-1258
For
Retatrutide
by Hydro Research Peptides· batch HR-2026-2051
For
Retatrutide
by Profound Aminos· batch White Cap
For
Retatrutide
by NG Peptide· batch rt30-6174
For
Retatrutide
by Forge Performance Co.· batch Clear Blue Cap
For
Retatrutide
by EZ Peptides· batch EZP-3P2005222026-02
For
Retatrutide
by EZ Peptides· batch EZP-3P2005222026-02
For
Retatrutide
by EZ Peptides· batch EZP-3P2005222026-02
For
Retatrutide
by EZ Peptides· batch EZP-3P2005220226-02
For
Retatrutide
by Peptide Plugs· batch 126-01-SM
For
Retatrutide
by Peptide Plugs· batch 129-01-DK
For
Retatrutide
by Peptide Plugs· batch 124-03-SM
For
Retatrutide
by NG Peptide· batch RT10-17
For
Retatrutide
by Peptide Partners· batch SPL-4092
For
Retatrutide
by Voltera Sciences· batch RT60.05.28.26
23 citations indexed for Retatrutide
animal · 2026
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.
review · 2026
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.
rct · 2026
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.
Study · 2026
A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide
Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).
Study · 2026
Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes
Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
Study · 2026
Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease
Background and hypothesis Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D).